Compare DOLE & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOLE | CRVS |
|---|---|---|
| Founded | 1851 | 2014 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2021 | 2016 |
| Metric | DOLE | CRVS |
|---|---|---|
| Price | $15.85 | $17.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 668.1K | ★ 2.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.28 | N/A |
| Revenue Next Year | $1.84 | N/A |
| P/E Ratio | $106.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.52 | $2.54 |
| 52 Week High | $16.51 | $26.95 |
| Indicator | DOLE | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 53.72 | 48.92 |
| Support Level | $15.60 | $6.65 |
| Resistance Level | $16.51 | $26.95 |
| Average True Range (ATR) | 0.35 | 1.28 |
| MACD | -0.05 | -0.83 |
| Stochastic Oscillator | 20.76 | 16.06 |
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).